Suzhou Gracell Biotechnologies Co., Ltd.

Main study objectives 1. To evaluate the safety and tolerability of GC012F injection in the treatment of refractory systemic lupus erythematosus (SLE) study participants and determine the recommended dose (Recommended Phase II Dose, RP2D) of the Phase II clinical study. Secondary study objectives 1. To further evaluate the safety of GC012F injection in the treatment of refractory SLE study participants; 2. To evaluate the effectiveness of GC012F injection in the treatment of refractory SLE study participants; 3. To evaluate the pharmacokinetic and pharmacodynamic characteristics of GC012F injection and its expansion and persistence in the study participants; 4. To evaluate the immunogenicity of GC012F injection in the study participants; 5. To further evaluate the effectiveness of GC012F injection.

Purpose of Phase I study: To evaluate the safety and tolerability of GC012F injection in the treatment of relapsed/refractory multiple myeloma subjects, and to determine the recommended dose (RP2D) for Phase II clinical study; to evaluate the effectiveness, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of GC012F injection in the treatment of relapsed/refractory multiple myeloma subjects Purpose of Phase II study: To evaluate the effectiveness of GC012F injection in the treatment of relapsed/refractory multiple myeloma subjects; to evaluate the safety, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of GC012F injection in the treatment of relapsed/refractory multiple myeloma subjects